Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Monday, March 11, 2019 at 4:00 PM to 4:30 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Advertisement

Currently submitted to: JMIR Cancer

Date Submitted: Apr 16, 2019
Open Peer Review Period: Apr 23, 2019 - Jun 3, 2019
(closed for review but you can still tweet)

NOTE: This is an unreviewed Preprint

Warning: This is a unreviewed preprint (What is a preprint?). Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn (a note “no longer under consideration” will appear above).

Peer-review me: Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period (in this case, a “Peer-Review Me” button to sign up as reviewer is displayed above). All preprints currently open for review are listed here. Outside of the formal open peer-review period we encourage you to tweet about the preprint.

Citation: Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author).

Final version: If our system detects a final peer-reviewed “version of record” (VoR) published in any journal, a link to that VoR will appear below. Readers are then encourage to cite the VoR instead of this preprint.

Settings: If you are the author, you can login and change the preprint display settings, but the preprint URL/DOI is supposed to be stable and citable, so it should not be removed once posted.

Submit: To post your own preprint, simply submit to any JMIR journal, and choose the appropriate settings to expose your submitted version as preprint.

Development of a computer-based algorithm for supporting community pharmacists in providing personalised lifestyle interventions for men with prostate cancer

  • Sara Faithfull; 
  • Karen Poole; 
  • Agnieszka Lemanska; 
  • Bruce Griffin; 
  • Ralph Manders; 
  • Jonathan Aning; 
  • John Marshall; 
  • Lauren Turner; 
  • John Saxton

Background:

The number of people living with and beyond a cancer diagnosis has increased, however survivors may experience long-term side-effects from treatment that can impact on physical fitness and cardiovascular health. Lifestyle interventions enhance outcomes after cancer treatment but innovations and technology are needed to provide consistency and scalability. Interventions to support exercise and dietary modification in secondary care settings have been limited by the lack of personalisation, clinician time and resources. Community pharmacies are well positioned to provide lifestyle advice for people with cancer and long-term conditions. This study is the first to develop a tailored lifestyle intervention using a computer algorithm to enable community pharmacists to provide personalised advice for cancer patients.

Objective:

To create a computer-based algorithm to support community pharmacists to deliver a tailored lifestyle intervention for men during and after treatment for prostate cancer.

Methods:

An observational study was conducted at two UK centres involving 83 men with prostate cancer who were 3-36 months’ post-diagnosis. Physical fitness, strength and cardiovascular health were assessed. Qualitative interviews were undertaken with 20 participants to understand their interpretation of the assessment and analysed using a framework analysis. These data were used to inform our computer-based algorithm and lifestyle prescriptions.

Results:

Physical fitness varied across participants. Limb strength was categorised with upper body strength low for 40% of men compared to their age (40 out of 83) and lower limb strength (44 of 83) 53% of men were low in comparison to age normative values. The Siconolfi step test provided classification of cardiopulmonary fitness with 26.5% (22 of 83) men unable to complete level 1 with very low physical fitness and 41% (34 of 83) of men moderate completing stage 2 of the test. Cardiovascular risk was categorised as high (>20% QRISK2) in 41% of men contributed to by the number of men who had a high hip to waist ratio 72 of 83 men (86.7%) indicating abdominal fat. Three emergent themes from the qualitative analysis highlighted different perceptions of the physical assessment experience. The algorithm provided a clear pathway for decision making, that it was safe and effective to enable community pharmacists to prescribe tailored lifestyle advice for men with prostate cancer.

Conclusions:

We have developed a computer algorithm that uses simple, safe and validated assessments to provide tailored lifestyle advice which addresses specific areas of cardiovascular risk, strength and physical fitness in men with prostate cancer. It generates a real-time lifestyle prescription at the point of care and has been integrated into the software platform used by pharmacies in the UK. The algorithm was integrated into the software platform used by pharmacies within the UK.

ClinicalTrial:

The study was approved by the UK National Research Ethics Service REC 14/LO/0495 IRAS project ID 148309.


 Citation

Please cite as:

Faithfull S, Poole K, Lemanska A, Griffin B, Manders R, Aning J, Marshall J, Turner L, Saxton J

Development of a computer-based algorithm for supporting community pharmacists in providing personalised lifestyle interventions for men with prostate cancer

JMIR Preprints. 16/04/2019:14395

DOI: 10.2196/preprints.14395

URL: https://preprints.jmir.org/preprint/14395


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.